Company news

Sutro Biopharma, Inc. news in 2024

Sutro Biopharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

December 9, 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

November 12, 2024

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

October 31, 2024

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 19, 2024

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

September 13, 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

September 10, 2024

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

August 21, 2024

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

August 12, 2024

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

July 8, 2024

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

May 12, 2024

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

April 29, 2024

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

April 1, 2024

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

March 24, 2024

Decks in 2024